Published in Arthritis Res Ther on December 10, 2009
Acute coronary events. Circulation (2012) 1.54
17-β Estradiol reduces atherosclerosis without exacerbating lupus in ovariectomized systemic lupus erythematosus-susceptible LDLr(-/-) mice. Atherosclerosis (2013) 1.40
Excess atherosclerosis in systemic lupus erythematosus,-A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls. PLoS One (2017) 1.37
Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. Am J Epidemiol (2012) 1.27
Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther (2012) 1.11
Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients. PLoS One (2012) 1.11
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol (2011) 0.96
Early vascular alterations in SLE and RA patients--a step towards understanding the associated cardiovascular risk. PLoS One (2012) 0.88
Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation. J Inflamm Res (2010) 0.86
Is preclinical autoimmunity benign?: The case of cardiovascular disease. Rheum Dis Clin North Am (2014) 0.84
Prospective cohort studies on risk factors for cardiovascular events in systemic lupus erythematosus: a major challenge. Arthritis Res Ther (2010) 0.83
Atherosclerosis in systemic lupus erythematosus. J Cardiovasc Pharmacol (2013) 0.83
Cardiovascular involvement in autoimmune diseases. Biomed Res Int (2014) 0.82
Rapidly progressive coronary artery disease as the first manifestation of antiphospholipid syndrome. BMJ Case Rep (2014) 0.81
Cardiovascular disease in latin american patients with systemic lupus erythematosus: a cross-sectional study and a systematic review. Autoimmune Dis (2013) 0.80
Cardiovascular Events in Systemic Lupus Erythematosus: A Nationwide Study in Spain From the RELESSER Registry. Medicine (Baltimore) (2015) 0.80
Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus. Clin Rheumatol (2011) 0.79
Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. Clin Exp Immunol (2015) 0.78
Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up. Arthritis Res Ther (2015) 0.77
Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials. Arthritis Rheumatol (2016) 0.77
Survival rates and risk factors for mortality in systemic lupus erythematosus patients in a Chinese center. Clin Rheumatol (2014) 0.76
Pathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for intervention. J Intern Med (2015) 0.76
Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations. Sci Rep (2016) 0.76
Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies. RMD Open (2015) 0.76
Anti-phospholipid Antibodies and Smoking: An Overview. Clin Rev Allergy Immunol (2017) 0.75
The vascular phenotype of children with systemic lupus erythematosus. Pediatr Nephrol (2015) 0.75
Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation. Lupus Sci Med (2016) 0.75
[Frequency, clinical implication and prognostic value of lymphopenia in systemic lupus erythematosus: case-control study]. Pan Afr Med J (2015) 0.75
Loss of Immune Tolerance Is Controlled by ICOS in Sle1 Mice. J Immunol (2016) 0.75
Systemic lupus erythematosus and thrombosis. Thromb J (2015) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum (1982) 67.54
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 16.11
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 7.86
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 6.88
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol (1997) 6.10
Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum (2001) 5.36
Inflammation as a cardiovascular risk factor. Circulation (2004) 4.26
Mortality in systemic lupus erythematosus. Arthritis Rheum (2006) 3.61
Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation (2001) 2.72
von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J (2002) 2.66
Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med (1992) 2.39
Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation (2001) 2.37
Systemic lupus erythematosus and the risk of cardiovascular disease: results from the nurses' health study. Arthritis Rheum (2009) 2.26
von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation (2008) 2.20
Premature atherosclerotic cardiovascular disease in systemic lupus erythematosus. Arthritis Rheum (2007) 1.86
Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood (2007) 1.79
Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum (2004) 1.75
Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood (2004) 1.57
Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) (1989) 1.54
Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation (2004) 1.52
Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum (2009) 1.48
Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci U S A (1990) 1.46
Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum (1988) 1.44
Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum (2005) 1.41
Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum (2003) 1.38
Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol (2004) 1.33
Brachial endothelial function is impaired in patients with systemic lupus erythematosus. J Rheumatol (2002) 1.26
Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology (Oxford) (2004) 1.24
Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum (2006) 1.23
Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus (2006) 1.20
Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol (1994) 1.15
Patients with systemic lupus erythematosus and Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response? Ann Rheum Dis (1992) 1.13
Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Rheum (2006) 1.09
Stimulation of von Willebrand factor antigen release by immunoglobulin from thrombosis prone patients with systemic lupus erythematosus and the anti-phospholipid syndrome. Br J Rheumatol (1993) 1.06
Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis (2007) 1.02
Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Arthritis Rheum (1996) 1.01
TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus (2003) 0.98
Relationship between lupus nephritis activity and the serum level of soluble VCAM-1. Lupus (1998) 0.95
Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients form a defined population. Medicine (Baltimore) (1992) 0.94
Increased release of von Willebrand factor antigen from endothelial cells by anti-DNA autoantibodies. Ann Rheum Dis (1996) 0.94
Decreased binding of annexin v to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol (2004) 0.91
A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis (2009) 0.90
Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scand J Rheumatol (2008) 0.88
Anti-glycoprotein Ib/IX and IIb/IIIa antibodies in patients with antiphospholipid antibodies. Thromb Haemost (1994) 0.87
Carotid atherosclerosis and endothelial cell adhesion molecules as predictors of long-term outcome in chronic hemodialysis patients. Am J Nephrol (2007) 0.86
Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers? Vasc Health Risk Manag (2005) 0.84
Coexistence of anti-phospholipid antibodies and endothelial perturbation in systemic lupus erythematosus patients with ongoing prothrombotic state. Circulation (1997) 0.83
Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. Rheumatology (Oxford) (2008) 0.82
Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant? J Rheumatol (2000) 0.77
Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med (2008) 9.61
Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med (2008) 7.33
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet (2009) 5.75
Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. Nat Genet (2008) 5.00
Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci U S A (2007) 4.71
A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet (2002) 4.03
Lung recruitment maneuver depresses central hemodynamics in patients following cardiac surgery. Intensive Care Med (2005) 2.94
119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord (2004) 2.85
Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis (2009) 2.73
Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis (2009) 2.70
Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int (2012) 2.61
Horizontal transfer of an adaptive chimeric photoreceptor from bryophytes to ferns. Proc Natl Acad Sci U S A (2014) 2.42
MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet (2005) 2.32
Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc Natl Acad Sci U S A (2011) 2.14
Increased risk of systemic lupus erythematosus in 29,000 patients with biopsy-verified celiac disease. J Rheumatol (2012) 2.11
Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell (2006) 2.09
A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet (2008) 1.98
Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet (2007) 1.95
Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant (2009) 1.93
Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum (2005) 1.89
Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. Eur Heart J (2007) 1.84
Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation (2004) 1.67
Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int (2010) 1.66
Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol (2006) 1.60
Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum (2011) 1.60
Low serum levels of vitamin D in idiopathic inflammatory myopathies. Ann Rheum Dis (2012) 1.59
Slight increase of serum S-100B during porcine endotoxemic shock may indicate blood-brain barrier damage. Anesth Analg (2005) 1.57
Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. Lancet HIV (2016) 1.51
Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest (2015) 1.51
Angiopoietin-1/angiopoietin-2 ratio for prediction of preeclampsia. Am J Hypertens (2009) 1.51
Leukocytes, cytokines, growth factors and hormones in human skeletal muscle and blood after uphill or downhill running. J Physiol (2004) 1.49
Effect of a single dose of tobramycin on systemic inflammatory response-induced acute kidney injury in a 6-hour porcine model. Crit Care Med (2009) 1.48
Genetic variation in the transforming growth factor-beta1 gene is associated with susceptibility to IgA nephropathy. Nephrol Dial Transplant (2009) 1.48
Comparison of individuals with and without specific IgA antibodies to Chlamydia pneumoniae: respiratory morbidity and the metabolic syndrome. Chest (2002) 1.48
Selective recruitment maneuvers for lobar atelectasis: effects on lung function and central hemodynamics: an experimental study in pigs. Anesth Analg (2006) 1.47
Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J Thorac Cardiovasc Surg (2002) 1.44
Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Fertil Steril (2007) 1.43
Open Lung in Lateral Decubitus With Differential Selective Positive End-Expiratory Pressure in an Experimental Model of Early Acute Respiratory Distress Syndrome. Crit Care Med (2015) 1.43
Influence of Tracheal Obstruction on the Efficacy of Superimposed High-frequency Jet Ventilation and Single-frequency Jet Ventilation. Anesthesiology (2015) 1.42
Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis (2010) 1.41
Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum Mol Genet (2010) 1.41
Videolaryngoscopy: towards a new standard method for tracheal intubation in the ICU? Intensive Care Med (2013) 1.41
Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J (2009) 1.40
Endothelial function in resistance and conduit arteries and 5-year risk of cardiovascular disease. Circulation (2011) 1.40
Estimation of the possible economic effects of a sequential testing strategy with NT-proBNP before echocardiography in primary care. Clin Lab (2014) 1.39
[In Process Citation]. Lakartidningen (2015) 1.39
Simple function tests, but not the modified HAQ, correlate with radiological joint damage in rheumatoid arthritis. Scand J Rheumatol (2002) 1.39
Intrathecal ketorolac does not improve acute or chronic pain after hip arthroplasty: a randomized controlled trial. J Anesth (2014) 1.38
Novel non-coding RNAs in Dictyostelium discoideum and their expression during development. Nucleic Acids Res (2004) 1.35
Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol (2002) 1.35
Self-rated health is related to levels of circulating cytokines. Psychosom Med (2004) 1.34
Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation (2004) 1.34
Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther (2006) 1.34
Selective IgA deficiency in autoimmune diseases. Mol Med (2011) 1.31
A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum (2007) 1.31
Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2007) 1.30
Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol (2007) 1.28
International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum (2007) 1.28
Biomarkers of extracellular matrix metabolism (MMP-9 and TIMP-1) and risk of stroke, myocardial infarction, and cause-specific mortality: cohort study. PLoS One (2011) 1.26
Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes Care (2008) 1.26
A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis (2005) 1.26
Variations in assay protocol for the Dako cystatin C method may change patient results by 50% without changing the results for controls. Clin Chem Lab Med (2006) 1.25
Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr (2003) 1.23
Veno-venous extracorporeal CO2 removal for the treatment of severe respiratory acidosis: pathophysiological and technical considerations. Crit Care (2014) 1.23
The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum (2006) 1.23
Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr (2005) 1.22
Prevalence and pathophysiological mechanisms of elevated cardiac troponin I levels in a population-based sample of elderly subjects. Eur Heart J (2008) 1.21
Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum (2003) 1.20
Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol (2011) 1.18
Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum (2008) 1.18
Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis (2012) 1.18
Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther (2012) 1.17
Calibration of the Siemens cystatin C immunoassay has changed over time. Clin Chem (2011) 1.16
Does singing promote well-being?: An empirical study of professional and amateur singers during a singing lesson. Integr Physiol Behav Sci (2003) 1.16
Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Ann Neurol (2013) 1.16
T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol (2009) 1.15
Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum (2011) 1.13
Transcriptome-mining for single-copy nuclear markers in ferns. PLoS One (2013) 1.12
Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis (2009) 1.12
Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum (2013) 1.12
Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther (2012) 1.11